The emergence of drug-resistant TB remains a global health threat, with only one-third of individuals estimated to have multi-drug (MDR) or rifampicin-resistant (RR) TB diagnosed and treated annually. While culture-based methods remain the standard for drug susceptibility testing (DST), they are not widely available and have long turnaround times for results, resulting in delays in diagnosis, treatment failure, and ongoing transmission of resistant strains. In 2023, the WHO recommended using targeted next-generation sequencing (tNGS) for detecting and managing drug-resistant TB. ASLM organised a four-part series to help countries share best practices for implementing tNGS. In the second session of the series, Anita Suresh provided an overview of the results of the Seq & Treat study that generated evidence leading to the WHO recommendation of tNGS for the rapid detection of drug-resistant TB. The objective of this session was to enable participants to have a basic understanding of the tNGS workflow, analytical and clinical performance of tNGS in various settings, as well as the implementation toolkit for scaling up access to genomic sequencing for TB. Please follow the links here to view the recorded ECHO session and download the presentation slides.